Sera Prognostics (NASDAQ:SERA – Get Free Report) and TScan Therapeutics (NASDAQ:TCRX – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, profitability, institutional ownership and risk.
Earnings and Valuation
This table compares Sera Prognostics and TScan Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sera Prognostics | $70,000.00 | 1,144.02 | -$31.93 million | ($0.67) | -3.03 |
| TScan Therapeutics | $7.11 million | 1.94 | -$129.77 million | ($0.91) | -0.22 |
Sera Prognostics has higher earnings, but lower revenue than TScan Therapeutics. Sera Prognostics is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Sera Prognostics has a beta of 1.06, suggesting that its share price is 6% more volatile than the S&P 500. Comparatively, TScan Therapeutics has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500.
Institutional & Insider Ownership
54.6% of Sera Prognostics shares are owned by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are owned by institutional investors. 11.3% of Sera Prognostics shares are owned by insiders. Comparatively, 6.2% of TScan Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares Sera Prognostics and TScan Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sera Prognostics | -47,475.72% | -46.71% | -34.06% |
| TScan Therapeutics | -1,655.35% | -108.72% | -54.47% |
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Sera Prognostics and TScan Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sera Prognostics | 1 | 0 | 1 | 1 | 2.67 |
| TScan Therapeutics | 1 | 5 | 2 | 0 | 2.12 |
Sera Prognostics presently has a consensus price target of $5.50, suggesting a potential upside of 170.94%. TScan Therapeutics has a consensus price target of $2.67, suggesting a potential upside of 1,212.34%. Given TScan Therapeutics’ higher possible upside, analysts plainly believe TScan Therapeutics is more favorable than Sera Prognostics.
Summary
Sera Prognostics beats TScan Therapeutics on 8 of the 15 factors compared between the two stocks.
About Sera Prognostics
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
About TScan Therapeutics
TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for Sera Prognostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sera Prognostics and related companies with MarketBeat.com's FREE daily email newsletter.
